Smoking Cessation
Smoking Cessation Market

Smoking Cessation is the process of discontinuing tobacco smoking. When a person smokes tobacco in cigarettes, cigars or pipes, they absorb toxins that can lead to various health problems such as diabetes, cancer, chronic obstructive pulmonary disease (COPD), heart diseases, lung diseases, and others. 


The main barrier to smoking cessation is nicotine addiction. Some of the most usual nicotine withdrawal symptoms smokers face when they try to quit smoking include craving for smoking, mood swings, insomnia, constipation, increased appetite, anxiety, etc.


Smoking Cessation Epidemiological Segmentation 

The Epidemiological Segmentation of Smoking Cessation in 7MM from 2017 to 2030 is segmented as:- 

  • Total Diagnosed Prevalent Cases of Smokers
  • Gender-specific Diagnosed Prevalent Cases of Smokers
  • Age-specific Diagnosed Prevalent Cases of Smokers
  • Total Diagnosed Prevalent Cases of Smoking Cessation 


Smoking Cessation Epidemiology 

  • The total diagnosed prevalent population in 7MM in 2017 was 49,301,950 
  • The diagnosed prevalent cases of smokers in the United States for males were 19,303,046, whereas, for females, the cases were 15,985,886 in 2017


Smoking Cessation Market

Smoking Cessation market size in 7MM was USD 2,874.8 million in 2017 


Smoking Cessation Market Drivers

  • Research and Development
  • Increase in awareness
  • Government-mandated warnings on tobacco products 


Smoking Cessation Market Barriers

  • Relapse Cases
  • Social Attitudes and Personal Beliefs
  • Social Network Barrier
  • Patients are not able to use the benefit from Insurers and Health Plans 


Smoking Cessation Emerging Drugs

The emerging drugs of the Smoking Cessation market are 

  • AXS-05
  • Cytisinicline (Cytisine)
  • Nadolol (INV102)
  • NFL-101
  • Liraglutide

And many others. 


Smoking Cessation Key Players

The key players in the Smoking Cessation market are

  • Axsome Therapeutics
  • Achieve Life Sciences
  • Chronic Airway Therapeutics
  • Smoke Free Therapeutics (NFL Biosciences SAS)
  • Novo Nordisk

And many others.